单位:[1]Department of Urology, Beijing Friendship Hospital, Capital MedicalUniversity, Beijing 100050, China临床科室泌尿外科泌尿外科首都医科大学附属北京友谊医院[2]Department of Internal Medicine, Divisionof Nephrology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands[3]Department of Stomatology, Beijing Shijitan Hospital, Capital MedicalUniversity, Beijing 100038, China[4]Department of Biological Repositories,Zhongnan Hospital of Wuhan University, Wuhan 430071, China
Background As bladder cancer was recognized to be immunogenic, dozens of studies have focused on immune biology of BLCA, but little is known about its relationship with the long non-coding RNAs (lncRNAs). Methods LASSO Cox regression model was used to establish immune-related lncRNAs signature (IRLS) in BLCA. The immune infiltration landscape of BLCA was conducted via ssGSEA and immunotherapy response was calculated through TIDE algorithm. Results A total of 82 immune-related lncRNAs were screened out according to spearman correlation analysis with the immune score (|R| > 0.4, p < 0.05). We selected 5 prognostic lncRNAs to construct immune-related lncRNAs signature (IRLS) through LASSO Cox regression analysis. Then we validated that 5 enrolled lncRNAs was downregulated in BLCA tissues and cells when compared with paracancerous tissues and normal bladder epithelium cell. The univariate and multivariate Cox regression analysis both demonstrated the IRLS was a robust independent prognostic factor in overall survival prediction with high accuracy. The GSVA and GSEA also suggested that the IRLS are involved in the immune-related biological processes and pathways which are very well known in the context of BLCA tumorigenesis. In addition, we found that IRLS is strikingly positive correlated with tumour microenvironment (TME) immune cells infiltration and expression of critical immune checkpoints, indicating that the poor prognosis might be caused partly by immunosuppressive TME. Finally, the results from the TIDE analysis revealed that IRLS could efficiently predict the clinical response of immunotherapy in BLCA. Conclusion We have developed a novel IRLS, which have a latent prognostic value for BLCA patients and might facilitate personalized counselling for immunotherapy.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81802550, 81902603]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2019M660041]; Beijing Postdoctoral Research FoundationChina Postdoctoral Science Foundation [ZZ2019-04]
第一作者单位:[1]Department of Urology, Beijing Friendship Hospital, Capital MedicalUniversity, Beijing 100050, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Cao R,Yuan L,Ma B,et al.Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA)[J].CANCER CELL INTERNATIONAL.2020,20(1):doi:10.1186/s12935-020-01362-0.
APA:
Cao, R,Yuan, L,Ma, B,Wang, G&Tian, Y.(2020).Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA).CANCER CELL INTERNATIONAL,20,(1)
MLA:
Cao, R,et al."Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA)".CANCER CELL INTERNATIONAL 20..1(2020)